Dr. Galsky on Resistance to Checkpoint Blockade in Metastatic Bladder Cancer

Partner | Cancer Centers | <b>The Tisch Cancer Institute</b>

Matthew Galsky, MD, professor of medicine, hematology and medical oncology, Mount Sinai Hospital, discusses resistance to checkpoint blockade in metastatic bladder cancer.

Matthew Galsky, MD, professor of medicine, hematology and medical oncology, Mount Sinai Hospital, discusses resistance to checkpoint blockade in metastatic bladder cancer.

There is a growing understanding about mechanisms of intrinsic and acquired resistance to checkpoint blockade in metastatic bladder cancer.

The main reason that patients don’t respond to checkpoint inhibitors is still not fully understood, says Galsky.